DENGUE affects tens of millions each year, producing the brutal symptoms that earned it the moniker "breakbone fever," but new research may have found the first-ever treatment for the virus.
Tests in cell cultures and mice found that a newly identified compound can effectively disarm the virus, stopping it from replicating and preventing disease, according to a study published Wednesday in the journal Nature.
And it appears to be effective whether taken protectively before infection or as a treatment after the virus is contracted.
It is an "exciting" development in the battle against dengue, according to Scott Biering and Eva Harris of the University of California, Berkeley's School of Public Health.
It "represents a major advance in the field of dengue therapeutics," the pair, who were not involved in the research, wrote in a review in Nature.
There is no doubt about the threat posed by the mosquito-borne dengue virus, which is estimated to infect at least 98 million people a year and is endemic in 128 countries worldwide.
It can cause intense flu-like symptoms, and sometimes develops into severe dengue which can be fatal.
And because there are four different strains of the virus, infection with one doesn't protect against another, and catching dengue a second time is often more serious.
No treatment exists so far, with efforts focusing instead on reducing transmission including a programme that infects mosquitoes with a disease-resistant bacteria.
A vaccine called Dengvaxia is approved for use only in some countries and is effective against a single strain.
- 'Unprecedented' -
Enter the unassumingly named JNJ-A07, a compound found by screening thousands of potential candidates, in a process researcher Johan Neyts described as like "looking for a needle in a haystack."
It turned out to be worth the wait.
Its effect "in infected animals is unprecedented," Neyts, who helped lead the research, told AFP.
"Even if treatment is started at the time of peak viral replication there is important antiviral activity," added Neyts, a professor of virology at the University of Leuven, Belgium.
JNJ-A07 works by targeting the interaction between two proteins in the dengue virus that are key to its replication.
Tests in cells, including from mosquitoes and humans, found it worked against all four dengue strains.
Dengue can evolve quickly, and so the team also examined how JNJ-A07 would fare as the virus mutates.
"It took us in the lab, in infected cells, almost half a year before we could obtain important resistance (to the treatment)," said Neyts.
"Given that the barrier to resistance is so high, it is very unlikely that this will clinically be a problem."
Intriguingly, the mutations that caused resistance also appeared to make the virus incapable of replicating in mosquito cells.
That could suggest that even if the virus develops resistance to treatment with JNJ-A07, it would no longer be transmissible via mosquitoes, effectively reaching a dead end in its host.
- Clinical trials in progress -
Promisingly, the compound was effective whether administered to mice before infection or afterwards.
The version of the compound reported in Nature has now been "further slightly optimised" and is in clinical development by Johnson & Johnson, Neyts said.
Various questions about JNJ-A07 remain, including whether it would be more effective if paired with other compounds, wrote Biering and Harris.
Another potential issue is whether it could increase vulnerability to reinfection.
When people contract dengue, the presence of the virus in their blood known as viraemia generally stimulates a potent immune response that protects them from future infection.
But in some people, the immune response is weaker and that leaves them vulnerable to reinfection with different strains, which can produce more serious symptoms.
Given that JNJ-A07 works to reduce viraemia, Biering and Harris cautioned that research is needed into whether this might leave people more susceptible to reinfection.
Despite the unknowns, Neyts said the study offers exciting possibilities.
"Seeing the compound work so potently in animals was breathtaking," he said, describing the research as "an amazing ride."
ETX Studio
Thu Oct 07 2021
No treatment for dengue exists so far, with efforts focusing instead on reducing transmission. - ETX Studio
Dua warga AS antara yang ditemui maut di bilik hotel di Thailand
Jabatan Negara Amerika Syarikat ambil maklum mengenai laporan mengenai dua warganegaranya yang ditemui mati di sebuah hotel di Thailand.
EU tolak label UNRWA sebagai organisasi pengganas
Ketua Dasar Luar Kesatuan Eropah (EU), Josep Borrell mengulangi penolakan blok itu melabel Agensi Bantuan dan Kerja Bangsa-Bangsa Bersatu untuk Pelarian Palestin (UNRWA) sebagai organisasi pengganas.
Mengimbau sedekad tragedi MH17
Pesawat MH17 Malaysia Airlines ditembak jatuh di timur Ukraine sejurus berlepas dari Lapangan Terbang Schiphol di Amsterdam, mengorbankan kesemua 283 penumpang dan 15 anak kapal di dalamnya.
Tragedi yang berlaku pada 17 Julai 2014 itu, kini memasuki tahun ke-10 kejadiannya.
Tragedi yang berlaku pada 17 Julai 2014 itu, kini memasuki tahun ke-10 kejadiannya.
Kerajaan teliti kaedah baharu lantikan tetap, pastikan kewangan negara lebih mampan
Kerajaan sedang meneliti kaedah baharu lantikan tetap bagi memastikan pengurusan kewangan negara yang lebih mampan.
PDRM gerak unit skuba forensik, K9 cari telefon, rantai Nur Farah Kartini hari ini
Proses mencari bahan bukti akan dimulakan sekitar jam 9 pagi di kawasan parit berhampiran ladang kelapa sawit berkenaan.
Bangkai pesawat MH17 tanpa sayap imbau kekejaman tragedi menyayat hati
Keadaan serpihan pesawat MH17 Malaysia Airlines (MAS) yang cuba dibina semula tanpa sayap, tayar, ekor dan tempat duduk penumpang cukup menggerunkan sekali gus mengingatkan pada kekejaman yang meragut
VOP akan diselesaikan dalam tempoh sebulan - Ahmad
Pelaksanaan Syarat Perubahan Harga (VOP) susulan penyasaran subsidi diesel dijangka diselesaikan dalam tempoh sebulan lagi, kata Timbalan Menteri Kerja Raya Datuk Seri Ahmad Maslan.
Industri minyak sawit disaran guna semula sisa untuk bahan api penerbangan mampan - Liew
Industri minyak sawit perlu mengkaji penggunaan semula sisa sebagai stok suapan penting untuk bahan api penerbangan mampan (SAF), di luar penggunaan tradisional minyak sawit.
SDG: UTP lahir pelajar berkemahiran, tinggi tanggungjawab sosial
UTP berhasrat mendidik pelajar bukan sahaja untuk mahir dalam aspek teknikal tetapi juga untuk menjadi warganegara yang bertanggungjawab.
MAA semak semula unjuran jualan kenderaan 2024 kepada 765,000 unit
Persatuan Automotif Malaysia (MAA) telah menyemak semula unjuran jualan kenderaan bermotor baharu bagi 2024 kepada 765,000 unit daripada anggaran sebelumnya sebanyak 740,000 unit.